IR@PKUHSC  > 北京大学临床肿瘤学院  > 胃肠肿瘤中心
学科主题临床医学
Combination of microtubule associated protein-tau and beta-tubulin III predicts chemosensitivity of paclitaxel in patients with advanced gastric cancer
Yu, Jingwei1; Gao, Jing1; Lu, Zhihao1; Gong, Jifang1; Li, Yanyan1; Dong, Bin2; Li, Zhongwu2; Zhang, Xiaotian1; Shen, Lin1
关键词Map-tau Tubb3 Paclitaxel Gastric Cancer
刊名EUROPEAN JOURNAL OF CANCER
2014-09-01
DOI10.1016/j.ejca.2014.06.017
50期:13页:2328-2335
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]CELL LUNG-CANCER ; BREAST-CANCER ; PREOPERATIVE CHEMOTHERAPY ; BINDING AGENTS ; EXPRESSION ; MARKER ; RESISTANCE ; TAXANES ; SENSITIVITY ; DOXORUBICIN
英文摘要

Aim: To investigate the role of microtubule associated proteiti-tau (MAP-tau) and beta-tubulin III (TUBB3) in predicting the chemosensitivity of paclitaxel in patients with advanced gastric cancer (GC).

Methods: MAP-tau and TUBB3 expressions were detected using immunohistochemistry in 244 advanced GC patients prior to chemotherapy. The associations of MAP-tau and TUBB3 expressions with paclitaxel sensitivity were assessed using in vitro and in vivo xenograft analysis.

Results: A total of 149 patients receiving paclitaxel plus capecitabine (cohort 1) and 95 patients receiving cisplatin plus capecitabine (cohort 2) were included in this study. In cohort 1, the clinical benefit rate (CBR), median progression-free survival (PFS) and overall survival (OS) were found to be significantly higher in patients with low levels of MAP-tau and TUBB3 expressions and were significantly higher than those in patients with high levels of MAP-tau and TUBB3 expressions (CBR: 72.2% versus 35.9%; PFS: 271 versus 102 days; OS: 394 versus 173 days; all P < 0.05). This was not observed in cohort 2. In in vitro studies, the sensitivity of paclitaxel in human gastric cancer cells was inversely correlated with the expression levels of MAP-tau and TUBB3, as in in vivo animal xenografts.

Conclusions: The combination of MAP-tau and TUBB3 was found to predict chemosensitivity to paclitaxel in gastric cancer in vitro and in vivo. This merits further study and may help, guide individual therapy. (C) 2014 Elsevier Ltd. All rights reserved.

语种英语
WOS记录号WOS:000340849800017
项目编号Z11110706730000 ; 81172110 ; 2012AA 02A 504
资助机构Beijing Municipal Science &amp ; Technology Commission Program ; National Natural Science Foundation of China ; National High Technology Research and Development Program
引用统计
被引频次:12[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/53733
专题北京大学临床肿瘤学院_胃肠肿瘤中心
北京大学临床肿瘤学院_消化肿瘤内科
北京大学临床肿瘤学院_病理科
北京大学临床肿瘤学院_中心实验室
作者单位1.Peking Univ Canc Hosp & Inst, Minist Educ, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China
2.Peking Univ Canc Hosp & Inst, Minist Educ, Dept Pathol, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China
推荐引用方式
GB/T 7714
Yu, Jingwei,Gao, Jing,Lu, Zhihao,et al. Combination of microtubule associated protein-tau and beta-tubulin III predicts chemosensitivity of paclitaxel in patients with advanced gastric cancer[J]. EUROPEAN JOURNAL OF CANCER,2014,50(13):2328-2335.
APA Yu, Jingwei.,Gao, Jing.,Lu, Zhihao.,Gong, Jifang.,Li, Yanyan.,...&Shen, Lin.(2014).Combination of microtubule associated protein-tau and beta-tubulin III predicts chemosensitivity of paclitaxel in patients with advanced gastric cancer.EUROPEAN JOURNAL OF CANCER,50(13),2328-2335.
MLA Yu, Jingwei,et al."Combination of microtubule associated protein-tau and beta-tubulin III predicts chemosensitivity of paclitaxel in patients with advanced gastric cancer".EUROPEAN JOURNAL OF CANCER 50.13(2014):2328-2335.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Yu, Jingwei]的文章
[Gao, Jing]的文章
[Lu, Zhihao]的文章
百度学术
百度学术中相似的文章
[Yu, Jingwei]的文章
[Gao, Jing]的文章
[Lu, Zhihao]的文章
必应学术
必应学术中相似的文章
[Yu, Jingwei]的文章
[Gao, Jing]的文章
[Lu, Zhihao]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。